DexCom Statistics

Total Valuation

DexCom has a market cap or net worth of MXN 655.68 billion. The enterprise value is 653.37 billion.

Market Cap	655.68B
Enterprise Value	653.37B

Important Dates

The next estimated earnings date is Thursday, July 24, 2025.

Earnings Date	Jul 24, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	392.11M
Shares Outstanding	n/a
Shares Change (YoY)	-3.45%
Shares Change (QoQ)	+0.20%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	389.33M

Valuation Ratios

The trailing PE ratio is 59.94 and the forward PE ratio is 38.27.

PE Ratio	59.94
Forward PE	38.27
PS Ratio	7.73
PB Ratio	14.15
P/TBV Ratio	14.93
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 37.38, with an EV/FCF ratio of 55.58.

EV / Earnings	59.73
EV / Sales	8.05
EV / EBITDA	37.38
EV / EBIT	52.80
EV / FCF	55.58

Financial Position

The company has a current ratio of 1.50, with a Debt / Equity ratio of 1.14.

Current Ratio	1.50
Quick Ratio	1.27
Debt / Equity	1.14
Debt / EBITDA	2.89
Debt / FCF	4.49
Interest Coverage	33.12

Financial Efficiency

Return on equity (ROE) is 23.72% and return on invested capital (ROIC) is 8.16%.

Return on Equity (ROE)	23.72%
Return on Assets (ROA)	5.98%
Return on Invested Capital (ROIC)	8.16%
Return on Capital Employed (ROCE)	17.03%
Revenue Per Employee	8.27M
Profits Per Employee	1.07M
Employee Count	10,300
Asset Turnover	0.63
Inventory Turnover	2.90

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -24.09% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-24.09%
50-Day Moving Average	1,642.05
200-Day Moving Average	2,120.25
Relative Strength Index (RSI)	53.48
Average Volume (20 Days)	1,022

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	2.50

Income Statement

In the last 12 months, DexCom had revenue of MXN 84.78 billion and earned 10.94 billion in profits. Earnings per share was 27.23.

Revenue	84.78B
Gross Profit	50.39B
Operating Income	12.93B
Pretax Income	14.94B
Net Income	10.94B
EBITDA	17.53B
EBIT	12.93B
Earnings Per Share (EPS)	27.23

Full Income Statement

Balance Sheet

The company has 55.21 billion in cash and 52.80 billion in debt, giving a net cash position of 2.42 billion.

Cash & Cash Equivalents	55.21B
Total Debt	52.80B
Net Cash	2.42B
Net Cash Per Share	n/a
Equity (Book Value)	46.33B
Book Value Per Share	118.15
Working Capital	31.00B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 19.71 billion and capital expenditures -7.95 billion, giving a free cash flow of 11.76 billion.

Operating Cash Flow	19.71B
Capital Expenditures	-7.95B
Free Cash Flow	11.76B
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 59.43%, with operating and profit margins of 15.25% and 12.90%.

Gross Margin	59.43%
Operating Margin	15.25%
Pretax Margin	17.62%
Profit Margin	12.90%
EBITDA Margin	20.68%
EBIT Margin	15.25%
FCF Margin	13.87%

Dividends & Yields

DexCom does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	3.45%
Shareholder Yield	3.45%
Earnings Yield	1.67%
FCF Yield	1.79%

Stock Splits

The last stock split was on June 13, 2022. It was a forward split with a ratio of 4.

Last Split Date	Jun 13, 2022
Split Type	Forward
Split Ratio	4

Scores

DexCom has an Altman Z-Score of 6.35.

Altman Z-Score	6.35
Piotroski F-Score	n/a